Dr Jerry, it seems like the medical community is still somewhat sceptical of MANF's chances of providing a solution to PD and other conditions, otherwise wouldn't one of the larger Pharma companies step in to partner with Amarantus? Why isn't this industry more excited about the opportunities that potentially exist with MANF? I'm sure all of us longs would love to get your opinion on this.
Disclosure: I'm long 95k shares and am excited about this company but I'm also a realist and don't want to just blindly invest in a company where this no future
Quote: "Second, Gerald has stuck to his guns by moving ahead with delivery of MANF using CED and micro catheters versus viral vectors. Expect a jv with nsGene or similar company that uses microcathters".
Dr Jerry: I so appreciate your continued support and feedback. I just want to make sure that things are put in perspective. If AMBS partners with nsGene (or similar company)...I am doubtful if that it the type of JV that most of us are looking for....it appears to be a drug delivery partnership. I believe most are looking for a Pharma. partner that will infuse a large chunk of cash up front to fund MANF trials. In summary, what you have shared and outlined would be considered a huge success and big gain to enhance our MANF drug delivery mechanism.
News 
Market Data 
Discover 
